alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 75, Number 8 (Wednesday, January 13, 2010)]
[Notices]
[Page 1780]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-406]


=======================================================================
-----------------------------------------------------------------------

FARM CREDIT SYSTEM INSURANCE CORPORATION


Meetings

AGENCY: Farm Credit System Insurance Corporation Board; Regular 
Meeting.
SUMMARY: Notice is hereby given of the regular meeting of the Farm 
Credit System Insurance Corporation Board (Board).

DATE AND TIME: The meeting of the Board will be held at the offices of 
the Farm Credit Administration in McLean, Virginia, on January 21, 
2010, from 9 a.m. until such time as the Board concludes its business.

FOR FURTHER INFORMATION CONTACT: Roland E. Smith, Secretary to the Farm 
Credit System Insurance Corporation Board, (703) 883-4009, TTY (703) 
883-4056.

ADDRESSES: Farm Credit System Insurance Corporation, 1501 Farm Credit 
Drive, McLean, Virginia 22102.

SUPPLEMENTARY INFORMATION: Parts of this meeting of the Board will be 
open to the public (limited space available) and parts will be closed 
to the public. In order to increase the accessibility to Board 
meetings, persons requiring assistance should make arrangements in 
advance. The matters to be considered at the meeting are:

Open Session

A. Approval of Minutes

    <bullet> December 10, 2009 (Open and Closed)

B. New Business

    <bullet> Review of Insurance Premium Rates

Closed Session

    <bullet> Update on System Institution Risk

    Dated: January 7, 2010.
Roland E. Smith,
Secretary, Farm Credit System Insurance Corporation Board.
[FR Doc. 2010-406 Filed 1-12-10; 8:45 am]
BILLING CODE 6710-01-P
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT
No. 96-6178
GARETH JEROME WILSON, Plaintiff - Appellant, versus JANET RENO; UNITED STATES MARSHAL SERVICE; CHRISTINE WHITMAN, Governor of New Jersey; UNITED STATES PAROLE COMMISSION; JOHN HAHN, Warden of Petersburg Federal Correctional Institution, Defendants - Appellees.
Appeal from the United States District Court for the Eastern District of Virginia, at Alexandria. Albert V. Bryan, Jr., Senior District Judge. (CA-95-1570-AM) Submitted: April 9, 1996 Decided: May 30, 1996 Before MURNAGHAN and WILLIAMS, Circuit Judges, and PHILLIPS, Senior Circuit Judge. Affirmed by unpublished per curiam opinion. Gareth Jerome Wilson, Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Gareth Jerome Wilson filed a Petition for a Writ of Mandamus in the Eastern District of Virginia seeking to compel Respondents to dismiss a New Jersey indictment filed against him. The district court denied his requested relief without prejudice to his right to apply to the appropriate New Jersey court. Wilson appeals. Mandamus is a drastic remedy to be used only in extraordinary circumstances. Kerr v. United States Dist. Court , 426 U.S. 394, 402(1976). "[C]ourts are extremely reluctant to grant a writ of mandamus." In re Ford Motor Co. , 751 F.2d 274, 275 (8th Cir. 1984). In seeking mandamus relief, a petitioner carries the heavy burden of showing that he has no other adequate means to attain the relief and that his right to such relief is clear and indisputable. In re First Fed. Sav. & Loan Ass'n , 860 F.2d 135, 138 (4th Cir. 1988). Because Appellant may seek the requested relief in the appropriate New Jersey court, by habeas corpus or otherwise, we affirm. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
§ 19.5 Reference to Department regulations. ( a ) The provisions of 45 CFR part 73, establishing standards of conduct for all Department employees, are fully applicable to all Food and Drug Administration employees, except that such regulations shall be applicable to special government employees, i.e., consultants to the Food and Drug Administration, only to the extent stated in subpart L of 45 CFR part 73.
( b ) The provisions of 45 CFR part 73a supplement the Department standards of conduct and apply only to Food and Drug Administration employees except special government employees.
§ 556.286 Flunixin. ( a ) *Acceptable daily intake (ADI).* The ADI for total residue of flunixin is 0.72 μg/kg of body weight per day.
( b ) *Tolerances.* The tolerances for flunixin are: ( 1 ) *Cattle.* ( i ) Liver (target tissue): 125 ppb flunixin free acid (marker residue).
( ii ) Muscle: 25 ppb flunixin free acid.
( iii ) Milk: 2 ppb 5-hydroxy flunixin (marker residue).
( 2 ) *Swine.* ( i ) Liver (target tissue): 30 ppb flunixin free acid (marker residue).
( ii ) Muscle: 25 ppb flunixin free acid.
( c ) *Related conditions of use.* See §§ 522.956, 522.970, 522.1664, and 524.970 of this chapter.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                           9,247
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 137,807
<CURRENT-LIABILITIES>                           19,195
<BONDS>                                         94,599
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         3,438
<OTHER-SE>                                      12,274
<TOTAL-LIABILITY-AND-EQUITY>                   137,807
<SALES>                                              0
<TOTAL-REVENUES>                                20,080
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                 6,858
<LOSS-PROVISION>                                   774
<INTEREST-EXPENSE>                               5,638
<INCOME-PRETAX>                                  6,810
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              6,810
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     6,810
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
<PAGE>   1
                                  EXHIBIT 21.1

                      SUBSIDIARIES OF DATA DIMENSIONS, INC.


<TABLE>
<CAPTION>
                                                    Jurisdiction
                                                        of
                                                    Incorporation
                                                    -------------

<S>                                                 <C>
Data Dimensions Ireland Limited                     Ireland

Data Dimensions (UK) Limited                        England

Data Dimensions Information Services, Inc.          California

Data Dimensions FSC, Inc.                           Guam

ST Labs, Inc.                                       Washington (1)
</TABLE>


(1) ST Labs, Inc. was merged with Data Dimensions, Inc., effective
February 1, 1999.
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

          Date of Report (Date of earliest event reported) May 8, 2000

                        Investment Properties Associates
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         New York                       0-5537                  13-2647723
----------------------------         ------------           -------------------
(State or other jurisdiction         (Commission              (IRS Employer
     of incorporation)               File Number)           Identification No.)

60 East 42nd Street, New York, New York                           10165
----------------------------------------                        ----------
(Address of principal executive offices)                        (Zip Code)

Registrant's telephone number, including area code (212) 687-6400

          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

<PAGE>

ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.

Registrant issued a press release on May 8, 2000, which reported that it has
concluded the sale of 245 Fifth Avenue and 261 Fifth Avenue, New York, N.Y. for
$135,000,000. The Purchaser is a fund controlled by Koll Bren Schreiber Realty
Advisors Inc., a Delaware corporation.

A copy of the press release reporting such event is attached hereto as Exhibit
99 and incorporated herein by reference.

(c)   Exhibits.

      Exhibit No.    Description
      -----------    -----------

      Exhibit 99     Press Release of Company, dated May 8, 2000

<PAGE>

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            INVESTMENT PROPERTIES ASSOCIATES

                                            BY:   /s/ Irving Schneider
                                               ---------------------------------
                                               Irving Schneider, General Partner

Date:  May 10, 2000
##### 



CORPORATE
INCENTIVE PLAN FY '07
 Objective:
 Plan Summary:
  WorldwideConsolidated ExideParticipant Category
    
    Weighting
    
    
    Division WeightingDivision Participant
    
    
    25%
    
    
    
    75%Corporate
    
    
    100%
    FY07 ACTUAL RESULTS
    
    Year End PayoutFY07 Actual EP results in a payout of 50% of the target
    
    Payout at 50%FY07 Actual EP at the midpoint between FY06 Actual
    
    Payout at 100%FY07 Actual EP equals FY07 Budgeted EP
    
    Payout at 200%




---



##### 



CORPORATE INCENTIVE PLAN FY07
 EXAMPLE  DIVISION PARTICIPANT
 
 PAYOUTWEIGHTING
    
    RESULTS
    
    PERCENTAGE
    
    PAYOUT AMOUNTDIVISION FY07 EP
    
    
    75
    %
    
    FY07 DIVISION EP
PRODUCES AN
EARNED PAYOUT OF
110% OF TARGET
    
    
    110
    %
    
    $
    6,187.50EXIDE FY07 EP
    
    
    25
    %
    
    FY07 EXIDE EP
EQUALS MIDPOINT
OR TARGET
    
    
    100
    %
    
    $
    1,875.00TOTAL
    
    
    
    
    
    
    
    
    
    
    
    $
    8,06250
 EXAMPLE  CORPORATE PARTICIPANT
 PAYOUTWEIGHTING
    
    RESULTS
    
    PERCENTAGE
    
    PAYOUT AMOUNTEXIDE FY07 EP
    
    
    100
    %
    
    FY07 EXIDE EP
EQUALS MIDPOINT
OR TARGET
    
    
    100
    %
    
    $
    7,500
 Points to remember:
 
    
    Payout will be after FY07 results have been finalized and audited
    
    Participation is at the discretion of the Company.
    
    Participation is determined on a yearly basis.
    
    The participant must be in an eligible position and employed by Exide at the time of payout.
    
    The Company must meet a cash/liquidity threshold net the cost of the plan as of 3/31/07.
    
    FY07 EP must equal or exceed the 50% payout level for a payout to be made.
    
    Questions of interpretation and all disputes will be resolved by the EP
Committee, consisting of the President and CEO, the EVP and CFO, and the EVP of
Human Resources.
§ 520.622b Diethylcarbamazine citrate syrup. ( a ) ( 1 ) *Specifications.* Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.
( 2 ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( 3 ) *Conditions of use.* ( i ) The drug is indicated for use in dogs for the prevention of infection with *Dirofilaria immitis* and *T. canis* and *T. leonina.* It is also indicated for treatment of ascarid infections of *T. canis* and *T. leonina* in dogs and *T. cati* in cats.
( ii ) For prevention of heartworm and ascarid infections in dogs, the drug may be added to the daily diet at a dosage rate of 3.0 milligrams per pound of body weight per day or given directly by mouth at the same dosage rate. For treatment of ascarid infections in dogs and cats, the drug is administered at a dosage level of 25 to 50 milligrams per pound of body weight preferably administered immediately after feeding.
( iii ) Older dogs should be proven negative for the presence of *Dirofilaria immitis* infection before administration of the drug. Those with proven infection of *Dirofilaria immitis* should be rendered negative using adulticidal and microfilaricidal drugs before administration of this drug.
( iv ) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( b ) [Reserved]
( c ) ( 1 ) *Specifications.* Each milliliter of syrup contains 60 milligrams of diethylcarbamazine citrate.
( 2 ) *Sponsor.* See No. 069043 in § 510.600(c) of this chapter.
( 3 ) *Conditions of use.* ( i ) The drug is used in dogs between 4 weeks and 8 months of age for the removal of ascarids (*Toxacara canis*) and in animals over 4 weeks of age for the prevention of heartworm disease (*Dirofilaria immitis*).
( ii ) The drug is administered (*a*) for removal of ascarids at a dosage of 50 milligrams per pound of body weight divided into two equal doses and administered 8 to 12 hours apart (morning and night), orally or mixed with either dry or wet food, and (*b*) for prevention of heartworm disease at a dosage of 3 milligrams per pound of body weight daily, orally or in food, in heartworm endemic areas, from the beginning of mosquito activity, during the mosquito season, and for 2 months following the end thereof.
( iii ) Dogs older than 8 months of age may be infected with *Dirofilaria immitis.* Use of the drug is contraindicated in dogs with active *D. immitis* infections.
( iv ) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 41 FR 28265, July 9, 1976; 44 FR 3967, Jan. 19, 1979; 47 FR 14150, Apr. 2, 1982; 47 FR 35186, Aug. 13, 1982; 49 FR 33997, Aug. 28, 1984; 50 FR 41489, Oct. 11, 1985; 53 FR 47027, Oct. 18, 1988; 61 FR 34728, July 3, 1996; 62 FR 35076, June 30, 1997; 62 FR 38906, July 21, 1997; 77 FR 4897, Feb. 1, 2012; 78 FR 21059, Apr. 9, 2013; 79 FR 28820, May 20, 2014; 83 FR 48945, Sept. 28, 2018]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States

              																								United States. Congress. Joint Economic Committee, 1956-					 and 	Eighty-Sixth Congress, 1959-1961.						"Study Paper Nos. 14 and 15 : Liquidity and Financial Institutions in the Postwar Period and Profits, Profit Markups, and Productivity: An Examination of Corporate Behavior Since 1947" in *Materials Prepared in Connection with the Study of Employment, Growth, and Price Levels for Consideration by the Joint Economic Committee, Congress of the United States*			(January 25, 1960).						https://fraser.stlouisfed.org/title/1244/item/3635, accessed on September 26, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsDevelopment of an Additively Manufactured Capacitive Humidity Sensor for the International Space StationThe ability to measure humidity on the International Space Station and other long-duration spaceflight missions is a crucial part of the onboard systems. For example, the Environmental Control and Life Support System (ECLSS) needs to know the amount of humidity in the air to make decisions about whether it should spend power to run the dehumidifier systems to attempt to reclaim that water. Other issues can arise if the humidity reaches too high of levels and condensation builds up on electrical components. With that in mind, it is vital that the spacecraft keeps spare sensors on board or has the ability to manufacture new sensors on demand. An additively manufactured sensor would be additionally beneficial because it would save space onboard that would normally be taken up by spares, save money from costly resupply missions, and allow the sensor to be constantly updated with the most effective design. This Technical Memorandum outlines a development process carried out to design, manufacture, and test an additively manufactured humidity sensor.Document ID20190025088Acquisition SourceMarshall Space Flight CenterDocument TypeTechnical Memorandum (TM)AuthorsChang, K. T.*(NASA Kennedy Space Center Cocoa Beach, FL, United States)*Rogers, A. T.Colby, J. A.Thompson, F. V.*(NASA Marshall Space Flight Center Huntsville, AL, United States)*Rolin, T. D.*(NASA Marshall Space Flight Center Huntsville, AL, United States)*Date AcquiredMay 11, 2019Publication DateMarch 1, 2019Subject CategorySpacecraft Instrumentation And AstrionicsReport/Patent NumberM-1482NASA/TM-2019?220131Distribution LimitsPublicCopyrightPublic Use Permitted.Available DownloadsNameType20190025088.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
Exhibit 32.2




CERTIFICATIONS





Pursuant to 18 U.S.C. § 1350, each of the undersigned officers of Discovery Laboratories, Inc. (the “Company”) hereby certifies that our Amendment No. 1 on Form 10-K/A for the fiscal year ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.





Date: April 27, 2012/s/ W. Thomas AmickW. Thomas AmickChairman of the Boardand Chief Executive Officer/s/ John G. CooperJohn G. CooperPresident and Chief Financial Officer





A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.




This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.  This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
EXHIBIT 99.2
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CirTran  Corporation on Form 10-QSB/A
for the period  ending  September  30, 2002,  as filed with the  Securities  and
Exchange Commission on the date hereof (the "Report"), Iehab Hawatmeh, President
and Chief  Executive  Officer of the Company,  certifies,  pursuant to 18 U.S.C.
Section 1350, as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of
2002, that:

     (1)  The Report fully  complies with the  requirements  of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
          material respects, the financial condition and result of operations of
          the Company.

January 21, 2003
                                /s/ Iehab J. Hawatmeh
                               __________________________________________
                               Iehab J. Hawatmeh
                               President and Chief Financial Officer
<PAGE>   1
                                                                    EXHIBIT 23.2

                       CONSENT OF INDEPENDENT ACCOUNTANTS

      We hereby consent to the use in the Prospectus constituting part of the
Registration Statement on Form S-4 of ARIS Corporation of our report dated 5 May
1998, relating to the financial statements of Barefoot Computer Training Limited
which appear in such Prospectus. We also consent to the references to us under
the headings "Experts" and "Selected Financial Data" in such Prospectus.
However, it should be noted that BDO Stoy Hayward has not prepared or certified
such "Selected Financial Data" nor do we take any responsibility for the
accuracy or completeness thereof.


BDO Stoy Hayward
Chartered Accountants
London, England
24 June 1999